Symbols / VVOS Stock $1.03 +0.00% Vivos Therapeutics, Inc.
VVOS (Stock) Chart
About
Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018. The company was founded in 2016 and is based in Littleton, Colorado.
Stock Fundamentals
Scroll to Statements| Market Cap | 13.89M | Enterprise Value | 25.30M | Income | -21.17M | Sales | 17.44M | Book/sh | 0.31 | Cash/sh | 0.15 |
| Dividend Yield | — | Payout | 0.00% | Employees | — | IPO | — | P/E | — | Forward P/E | -2.94 |
| PEG | — | P/S | 0.80 | P/B | 3.37 | P/C | — | EV/EBITDA | -1.36 | EV/Sales | 1.45 |
| Quick Ratio | 0.20 | Current Ratio | 0.24 | Debt/Eq | — | LT Debt/Eq | — | EPS (ttm) | -2.07 | EPS next Y | -0.35 |
| EPS Growth | — | Revenue Growth | 3.40% | Earnings | 2026-05-14 | ROA | -61.50% | ROE | -6.63% | ROIC | — |
| Gross Margin | 60.44% | Oper. Margin | -166.89% | Profit Margin | -121.37% | Shs Outstand | 13.49M | Shs Float | 12.75M | Short Float | 2.90% |
| Short Ratio | 2.70 | Short Interest | — | 52W High | 7.95 | 52W Low | 0.96 | Beta | 6.90 | Avg Volume | 197.43K |
| Volume | 195.29K | Target Price | $3.25 | Recom | Buy | Prev Close | $1.03 | Price | $1.03 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-22 | main | Ascendiant Capital | Buy → Buy | $3 |
| 2026-04-17 | main | HC Wainwright & Co. | Buy → Buy | $3 |
| 2025-12-03 | main | Ascendiant Capital | Buy → Buy | $6 |
| 2025-11-17 | init | HC Wainwright & Co. | — → Buy | $7 |
| 2025-09-09 | main | Ascendiant Capital | Buy → Buy | $7 |
| 2025-04-15 | main | Ascendiant Capital | Buy → Buy | $6 |
| 2024-11-20 | reit | Ascendiant Capital | Buy → Buy | $7 |
| 2024-11-19 | main | Alliance Global Partners | Buy → Buy | $6 |
| 2024-08-20 | main | Ascendiant Capital | Buy → Buy | $7 |
- Equity shortfall puts Vivos Therapeutics (NASDAQ: VVOS) at Nasdaq delisting risk - Stock Titan Wed, 22 Apr 2026 20
- Vivos Therapeutics Faces Nasdaq Listing Compliance Challenges - TipRanks Wed, 22 Apr 2026 21
- Vivos Therapeutics (VVOS) Upgraded to Buy: Here's What You Should Know - Yahoo Finance Mon, 05 Jan 2026 08
- Vivos Therapeutics stock price target lowered to $2.50 by H.C. Wainwright - Investing.com Mon, 20 Apr 2026 11
- VVOS | Vivos Therapeutics, Inc. Common Insider Trading - Quiver Quantitative Fri, 03 Apr 2026 02
- VVOS Stock Chart | VIVOS THERAPEUTICS INC (NASDAQ:VVOS) - ChartMill Fri, 10 Apr 2026 07
- Vivos Therapeutics (VVOS) Stock: Why Cash Position (Freefalls) 2026-04-16 - Trending Entry Points - Cổng thông tin điện tử tỉnh Lào Cai Fri, 17 Apr 2026 01
- Vivos grows on sleep apnea services, but operating loss hits $19.9M - Stock Titan Wed, 15 Apr 2026 20
- Vivos Therapeutics receives Nasdaq notice for stockholders’ equity deficiency By Investing.com - Investing.com UK Wed, 22 Apr 2026 20
- Vivos Therapeutics, Inc. to Release Full Year 2025 Financial Results and Conduct Conference Call on April 15, 2026 - Quiver Quantitative Wed, 15 Apr 2026 12
- Vivos investors get 2025 results and strategy update at 5 p.m. ET - Stock Titan Wed, 15 Apr 2026 12
- Sleep-disorder company Vivos gets $2.25M from repeat investor - Stock Titan ue, 07 Apr 2026 07
- Vivos Therapeutics (NASDAQ: VVOS) investor buys stock, pre-funded warrants - Stock Titan hu, 02 Apr 2026 07
- Vivos Therapeutics (NASDAQ: VVOS) gets $850,000 PIPE cash plus $1,400,000 bridge note conversion - Stock Titan Fri, 03 Apr 2026 07
- Vivos Therapeutics (VVOS) 10% holder reports large stock and warrant stakes - Stock Titan Fri, 10 Apr 2026 07
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
17.44
+16.05%
|
15.03
+8.91%
|
13.80
-13.87%
|
16.02
|
| Operating Revenue |
|
17.44
+16.05%
|
15.03
+8.91%
|
13.80
-13.87%
|
16.02
|
| Cost Of Revenue |
|
6.90
+14.79%
|
6.01
+8.72%
|
5.53
-7.91%
|
6.00
|
| Reconciled Cost Of Revenue |
|
6.90
+14.79%
|
6.01
+8.72%
|
5.53
-7.91%
|
6.00
|
| Gross Profit |
|
10.54
+16.89%
|
9.02
+9.04%
|
8.27
-17.45%
|
10.02
|
| Operating Expense |
|
30.44
+50.75%
|
20.19
-21.03%
|
25.57
-27.06%
|
35.05
|
| Selling General And Administration |
|
29.13
+48.54%
|
19.61
-21.39%
|
24.95
-27.44%
|
34.38
|
| Selling And Marketing Expense |
|
1.40
-19.12%
|
1.73
-29.83%
|
2.47
-53.80%
|
5.34
|
| General And Administrative Expense |
|
27.73
+55.09%
|
17.88
-20.47%
|
22.48
-22.60%
|
29.04
|
| Other Gand A |
|
27.73
+55.09%
|
17.88
-20.47%
|
22.48
-22.60%
|
29.04
|
| Total Expenses |
|
37.34
+42.50%
|
26.20
-15.74%
|
31.10
-24.26%
|
41.05
|
| Operating Income |
|
-19.89
-78.09%
|
-11.17
+35.41%
|
-17.30
+30.90%
|
-25.03
|
| Total Operating Income As Reported |
|
-19.89
-78.09%
|
-11.17
+35.41%
|
-17.30
+30.90%
|
-25.03
|
| EBITDA |
|
-18.59
-75.50%
|
-10.59
+36.49%
|
-16.68
+31.55%
|
-24.36
|
| Normalized EBITDA |
|
-18.59
-75.50%
|
-10.59
+48.22%
|
-20.45
+20.26%
|
-25.65
|
| Reconciled Depreciation |
|
1.31
+125.30%
|
0.58
-6.44%
|
0.62
-7.17%
|
0.67
|
| EBIT |
|
-19.89
-78.09%
|
-11.17
+35.41%
|
-17.30
+30.90%
|
-25.03
|
| Total Unusual Items |
|
—
|
—
|
3.78
+193.55%
|
1.29
|
| Total Unusual Items Excluding Goodwill |
|
—
|
—
|
3.78
+193.55%
|
1.29
|
| Special Income Charges |
|
—
|
—
|
0.00
-100.00%
|
1.29
|
| Other Special Charges |
|
—
|
—
|
—
|
-1.29
|
| Write Off |
|
—
|
—
|
—
|
0.00
|
| Net Income |
|
-21.23
-90.64%
|
-11.14
+18.02%
|
-13.58
+43.04%
|
-23.84
|
| Pretax Income |
|
-21.23
-90.64%
|
-11.14
+18.02%
|
-13.58
+43.04%
|
-23.84
|
| Net Non Operating Interest Income Expense |
|
—
|
—
|
—
|
0.00
|
| Interest Expense Non Operating |
|
—
|
—
|
—
|
0.00
|
| Net Interest Income |
|
—
|
—
|
—
|
0.00
|
| Interest Expense |
|
—
|
—
|
—
|
0.00
|
| Interest Income Non Operating |
|
—
|
—
|
—
|
—
|
| Interest Income |
|
—
|
—
|
—
|
—
|
| Other Income Expense |
|
-1.34
-3917.14%
|
0.04
-99.06%
|
3.71
+213.07%
|
1.19
|
| Other Non Operating Income Expenses |
|
-1.34
-3917.14%
|
0.04
+153.85%
|
-0.07
+35.64%
|
-0.10
|
| Gain On Sale Of Security |
|
—
|
—
|
3.78
|
—
|
| Tax Provision |
|
—
|
—
|
—
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-21.23
-90.64%
|
-11.14
+18.02%
|
-13.58
+43.04%
|
-23.84
|
| Net Income From Continuing Operation Net Minority Interest |
|
-21.23
-90.64%
|
-11.14
+18.02%
|
-13.58
+43.04%
|
-23.84
|
| Net Income From Continuing And Discontinued Operation |
|
-21.23
-90.64%
|
-11.14
+18.02%
|
-13.58
+43.04%
|
-23.84
|
| Net Income Continuous Operations |
|
-21.23
-90.64%
|
-11.14
+18.02%
|
-13.58
+43.04%
|
-23.84
|
| Normalized Income |
|
-21.23
-90.64%
|
-11.14
+35.86%
|
-17.36
+30.92%
|
-25.13
|
| Net Income Common Stockholders |
|
-21.23
-90.64%
|
-11.14
+18.02%
|
-13.58
+43.04%
|
-23.84
|
| Otherunder Preferred Stock Dividend |
|
—
|
—
|
—
|
—
|
| Diluted EPS |
|
—
|
-2.22
+80.07%
|
-11.14
+56.99%
|
-25.90
|
| Basic EPS |
|
—
|
-2.22
+80.07%
|
-11.14
+56.99%
|
-25.90
|
| Basic Average Shares |
|
—
|
5.02
+311.67%
|
1.22
+32.46%
|
0.92
|
| Diluted Average Shares |
|
—
|
5.02
+311.67%
|
1.22
+32.46%
|
0.92
|
| Diluted NI Availto Com Stockholders |
|
-21.23
-90.64%
|
-11.14
+18.02%
|
-13.58
+43.04%
|
-23.84
|
| Depreciation Amortization Depletion Income Statement |
|
1.31
+125.30%
|
0.58
-6.44%
|
0.62
-7.17%
|
0.67
|
| Depreciation And Amortization In Income Statement |
|
1.31
+125.30%
|
0.58
-6.44%
|
0.62
-7.17%
|
0.67
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
25.15
+64.56%
|
15.28
+42.44%
|
10.73
-21.79%
|
13.72
|
| Current Assets |
|
4.38
-41.34%
|
7.47
+203.66%
|
2.46
-54.63%
|
5.42
|
| Cash Cash Equivalents And Short Term Investments |
|
2.03
-67.59%
|
6.26
+281.01%
|
1.64
-53.31%
|
3.52
|
| Cash And Cash Equivalents |
|
2.03
-67.59%
|
6.26
+281.01%
|
1.64
-53.31%
|
3.52
|
| Receivables |
|
1.58
+267.67%
|
0.43
+112.87%
|
0.20
-55.80%
|
0.46
|
| Accounts Receivable |
|
1.58
+267.67%
|
0.43
+112.87%
|
0.20
-55.80%
|
0.46
|
| Gross Accounts Receivable |
|
2.46
+200.37%
|
0.82
+74.47%
|
0.47
-59.79%
|
1.17
|
| Allowance For Doubtful Accounts Receivable |
|
-0.88
-126.15%
|
-0.39
-45.52%
|
-0.27
+62.36%
|
-0.71
|
| Other Receivables |
|
—
|
—
|
—
|
—
|
| Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Other Current Assets |
|
0.77
-1.15%
|
0.78
+27.11%
|
0.62
-57.46%
|
1.45
|
| Total Non Current Assets |
|
20.77
+165.88%
|
7.81
-5.54%
|
8.27
-0.33%
|
8.30
|
| Net PPE |
|
7.92
+82.43%
|
4.34
-7.58%
|
4.70
-1.63%
|
4.78
|
| Gross PPE |
|
10.86
+52.45%
|
7.12
+1.40%
|
7.03
+7.58%
|
6.53
|
| Accumulated Depreciation |
|
-2.94
-5.61%
|
-2.78
-19.52%
|
-2.33
-32.69%
|
-1.75
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
3.09
+129.06%
|
1.35
+2.12%
|
1.32
+4.43%
|
1.26
|
| Construction In Progress |
|
0.00
-100.00%
|
1.86
+29.41%
|
1.44
+51.37%
|
0.95
|
| Other Properties |
|
4.57
+217.94%
|
1.44
-19.66%
|
1.79
-2.61%
|
1.84
|
| Leases |
|
3.20
+28.96%
|
2.48
+0.00%
|
2.48
+0.00%
|
2.48
|
| Goodwill And Other Intangible Assets |
|
12.62
+287.98%
|
3.25
-0.34%
|
3.26
+3.75%
|
3.15
|
| Goodwill |
|
8.57
+201.51%
|
2.84
+0.00%
|
2.84
+0.00%
|
2.84
|
| Other Intangible Assets |
|
4.04
+889.00%
|
0.41
-2.62%
|
0.42
+39.07%
|
0.30
|
| Non Current Prepaid Assets |
|
—
|
—
|
—
|
0.37
|
| Other Non Current Assets |
|
0.23
+5.56%
|
0.22
-29.64%
|
0.31
-17.91%
|
0.37
|
| Total Liabilities Net Minority Interest |
|
26.70
+264.28%
|
7.33
-28.97%
|
10.32
+15.70%
|
8.92
|
| Current Liabilities |
|
18.08
+263.12%
|
4.98
-31.71%
|
7.29
+6.99%
|
6.81
|
| Payables And Accrued Expenses |
|
7.67
+130.10%
|
3.33
-25.61%
|
4.48
+34.79%
|
3.32
|
| Payables |
|
2.48
+56.93%
|
1.58
-36.12%
|
2.47
+75.19%
|
1.41
|
| Accounts Payable |
|
1.68
+52.91%
|
1.10
-48.81%
|
2.15
+52.02%
|
1.41
|
| Current Accrued Expenses |
|
5.19
+196.01%
|
1.75
-12.66%
|
2.01
+4.97%
|
1.91
|
| Employee Benefits |
|
2.90
+138.03%
|
1.22
+0.00%
|
1.22
|
0.00
|
| Total Tax Payable |
|
0.80
+66.11%
|
0.48
+47.09%
|
0.33
|
—
|
| Current Debt And Capital Lease Obligation |
|
9.08
+1803.56%
|
0.48
+0.63%
|
0.47
+13.13%
|
0.42
|
| Current Debt |
|
8.35
|
—
|
—
|
—
|
| Other Current Borrowings |
|
8.35
|
—
|
—
|
—
|
| Current Capital Lease Obligation |
|
0.73
+52.41%
|
0.48
+0.63%
|
0.47
+13.13%
|
0.42
|
| Current Deferred Liabilities |
|
0.48
-46.54%
|
0.90
-58.09%
|
2.14
-26.93%
|
2.93
|
| Current Deferred Revenue |
|
0.48
-46.54%
|
0.90
-58.09%
|
2.14
-26.93%
|
2.93
|
| Other Current Liabilities |
|
0.85
+211.36%
|
0.27
+37.88%
|
0.20
+36.55%
|
0.14
|
| Total Non Current Liabilities Net Minority Interest |
|
8.63
+266.75%
|
2.35
-22.38%
|
3.03
+43.87%
|
2.11
|
| Long Term Debt And Capital Lease Obligation |
|
4.42
+327.25%
|
1.03
-31.95%
|
1.52
-23.72%
|
1.99
|
| Long Term Debt |
|
0.47
|
—
|
—
|
—
|
| Long Term Capital Lease Obligation |
|
3.95
+281.93%
|
1.03
-31.95%
|
1.52
-23.72%
|
1.99
|
| Non Current Deferred Liabilities |
|
0.00
-100.00%
|
0.10
-66.44%
|
0.29
+158.04%
|
0.11
|
| Non Current Deferred Revenue |
|
0.00
-100.00%
|
0.10
-66.44%
|
0.29
+158.04%
|
0.11
|
| Other Non Current Liabilities |
|
1.30
|
—
|
—
|
—
|
| Stockholders Equity |
|
-1.49
-118.73%
|
7.95
+1835.28%
|
0.41
-91.44%
|
4.80
|
| Common Stock Equity |
|
-1.49
-118.73%
|
7.95
+1835.28%
|
0.41
-91.44%
|
4.80
|
| Capital Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Common Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
9.29
+57.68%
|
5.89
+221.15%
|
1.83
+99.23%
|
0.92
|
| Ordinary Shares Number |
|
9.29
+57.68%
|
5.89
+221.15%
|
1.83
+99.23%
|
0.92
|
| Additional Paid In Capital |
|
123.87
+10.46%
|
112.14
+19.99%
|
93.46
+10.91%
|
84.27
|
| Retained Earnings |
|
-125.36
-20.32%
|
-104.19
-11.97%
|
-93.05
-17.09%
|
-79.47
|
| Minority Interest |
|
-0.06
|
0.00
|
—
|
—
|
| Total Equity Gross Minority Interest |
|
-1.55
-119.49%
|
7.95
+1835.28%
|
0.41
-91.44%
|
4.80
|
| Total Capitalization |
|
-1.02
-112.84%
|
7.95
+1835.28%
|
0.41
-91.44%
|
4.80
|
| Working Capital |
|
-13.69
-648.78%
|
2.50
+151.68%
|
-4.83
-247.59%
|
-1.39
|
| Invested Capital |
|
7.33
-7.82%
|
7.95
+1835.28%
|
0.41
-91.44%
|
4.80
|
| Total Debt |
|
13.50
+792.99%
|
1.51
-24.21%
|
2.00
-17.32%
|
2.41
|
| Net Debt |
|
6.79
|
—
|
—
|
—
|
| Capital Lease Obligations |
|
4.68
+209.52%
|
1.51
-24.21%
|
2.00
-17.32%
|
2.41
|
| Net Tangible Assets |
|
-14.11
-400.02%
|
4.70
+264.87%
|
-2.85
-272.22%
|
1.66
|
| Tangible Book Value |
|
-14.11
-400.02%
|
4.70
+264.87%
|
-2.85
-272.22%
|
1.66
|
| Dueto Related Parties Current |
|
—
|
—
|
—
|
—
|
| Interest Payable |
|
1.95
|
0.00
|
—
|
—
|
| Non Current Note Receivables |
|
—
|
—
|
—
|
—
|
| Notes Receivable |
|
—
|
—
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-15.26
-20.27%
|
-12.69
-6.24%
|
-11.95
+39.01%
|
-19.59
|
| Cash Flow From Continuing Operating Activities |
|
-15.26
-20.27%
|
-12.69
-6.24%
|
-11.95
+39.01%
|
-19.59
|
| Net Income From Continuing Operations |
|
-21.23
-90.64%
|
-11.14
+18.02%
|
-13.58
+43.04%
|
-23.84
|
| Depreciation Amortization Depletion |
|
1.31
+125.30%
|
0.58
-6.44%
|
0.62
-7.17%
|
0.67
|
| Depreciation And Amortization |
|
1.31
+125.30%
|
0.58
-6.44%
|
0.62
-7.17%
|
0.67
|
| Other Non Cash Items |
|
—
|
0.01
-87.36%
|
0.09
|
—
|
| Stock Based Compensation |
|
0.66
-13.25%
|
0.76
-31.10%
|
1.11
-53.84%
|
2.40
|
| Asset Impairment Charge |
|
—
|
—
|
—
|
0.00
|
| Operating Gains Losses |
|
—
|
0.03
+101.02%
|
-3.04
-487.07%
|
-0.52
|
| Gain Loss On Investment Securities |
|
—
|
0.03
+101.02%
|
-3.04
-527.71%
|
0.71
|
| Change In Working Capital |
|
4.00
+235.95%
|
-2.94
-202.65%
|
2.86
+67.39%
|
1.71
|
| Change In Receivables |
|
-0.22
+4.82%
|
-0.23
-189.41%
|
0.26
-65.82%
|
0.75
|
| Changes In Account Receivables |
|
-0.22
+4.82%
|
-0.23
-189.41%
|
0.26
-65.82%
|
0.75
|
| Change In Prepaid Assets |
|
0.05
+177.42%
|
-0.06
-106.80%
|
0.91
+729.09%
|
0.11
|
| Change In Payables And Accrued Expense |
|
4.14
+481.05%
|
-1.09
-194.03%
|
1.16
+356.89%
|
-0.45
|
| Change In Accrued Expense |
|
3.62
+9376.92%
|
-0.04
-109.24%
|
0.42
+144.85%
|
-0.94
|
| Change In Payable |
|
0.52
+150.00%
|
-1.05
-242.78%
|
0.73
+49.49%
|
0.49
|
| Change In Account Payable |
|
0.52
+150.00%
|
-1.05
-242.78%
|
0.73
+49.49%
|
0.49
|
| Change In Other Working Capital |
|
-0.51
+64.16%
|
-1.43
-134.70%
|
-0.61
-152.95%
|
1.15
|
| Change In Other Current Liabilities |
|
0.54
+517.05%
|
-0.13
-111.20%
|
1.15
+662.91%
|
0.15
|
| Investing Cash Flow |
|
-7.53
-1225.00%
|
-0.57
+33.41%
|
-0.85
+7.68%
|
-0.92
|
| Cash Flow From Continuing Investing Activities |
|
-7.53
-1225.00%
|
-0.57
+33.41%
|
-0.85
+7.68%
|
-0.92
|
| Net PPE Purchase And Sale |
|
-2.34
-312.15%
|
-0.57
+29.27%
|
-0.80
+13.10%
|
-0.92
|
| Purchase Of PPE |
|
-2.34
-312.15%
|
-0.57
+29.27%
|
-0.80
+13.10%
|
-0.92
|
| Capital Expenditure |
|
-2.34
-312.15%
|
-0.57
+29.27%
|
-0.80
+13.10%
|
-0.92
|
| Net Business Purchase And Sale |
|
-5.18
|
0.00
|
—
|
0.00
|
| Purchase Of Business |
|
-5.18
|
0.00
|
—
|
0.00
|
| Net Other Investing Changes |
|
—
|
—
|
-0.05
|
—
|
| Financing Cash Flow |
|
18.56
+3.82%
|
17.88
+63.65%
|
10.92
|
0.00
|
| Cash Flow From Continuing Financing Activities |
|
18.56
+3.82%
|
17.88
+63.65%
|
10.92
|
0.00
|
| Net Issuance Payments Of Debt |
|
10.64
|
0.00
|
—
|
0.00
|
| Issuance Of Debt |
|
10.67
|
0.00
|
—
|
—
|
| Repayment Of Debt |
|
-0.03
|
0.00
|
—
|
0.00
|
| Long Term Debt Issuance |
|
10.67
|
0.00
|
—
|
—
|
| Long Term Debt Payments |
|
-0.03
|
0.00
|
—
|
0.00
|
| Net Long Term Debt Issuance |
|
10.64
|
0.00
|
—
|
0.00
|
| Net Common Stock Issuance |
|
5.58
-28.48%
|
7.80
+94.90%
|
4.00
|
0.00
|
| Repurchase Of Capital Stock |
|
—
|
—
|
—
|
0.00
|
| Proceeds From Stock Option Exercised |
|
3.17
-72.26%
|
11.44
+43.01%
|
8.00
|
—
|
| Net Other Financing Charges |
|
-0.84
+38.50%
|
-1.36
-26.37%
|
-1.08
|
—
|
| Changes In Cash |
|
-4.23
-191.64%
|
4.62
+346.11%
|
-1.88
+90.85%
|
-20.51
|
| Beginning Cash Position |
|
6.26
+281.01%
|
1.64
-53.31%
|
3.52
-85.36%
|
24.03
|
| End Cash Position |
|
2.03
-67.59%
|
6.26
+281.01%
|
1.64
-53.31%
|
3.52
|
| Free Cash Flow |
|
-17.60
-32.77%
|
-13.26
-4.00%
|
-12.75
+37.84%
|
-20.51
|
| Interest Paid Supplemental Data |
|
0.00
-100.00%
|
0.01
|
0.00
|
0.00
|
| Income Tax Paid Supplemental Data |
|
—
|
—
|
—
|
—
|
| Common Stock Issuance |
|
5.58
-28.48%
|
7.80
+94.90%
|
4.00
|
0.00
|
| Issuance Of Capital Stock |
|
5.58
-28.48%
|
7.80
+94.90%
|
4.00
|
0.00
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
—
|
| Preferred Stock Payments |
|
—
|
—
|
—
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-22 View
- 8-K2026-04-15 View
- 10-K2026-04-15 View
- 8-K2026-04-03 View
- 42026-04-02 View
- 8-K2026-02-06 View
- 8-K2026-01-20 View
- 8-K2026-01-16 View
- 8-K2025-12-17 View
- 8-K2025-12-05 View
- 8-K2025-11-19 View
- 10-Q2025-11-19 View
- 8-K2025-11-04 View
- 8-K2025-10-24 View
- 8-K2025-09-18 View
- 8-K2025-09-12 View
- 8-K2025-08-20 View
- 10-Q2025-08-19 View
- 8-K2025-06-13 View
- 8-K2025-06-06 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|